BL,yeah I think so.
All imo here.
1) The big partner with leronlimb is waiting for the BLA submission and the outcome of the mono pivotal meeting with the FDA. They need the cash to get past that point.
2) They have a potential partner in the ProstaGene test, we've seen the name, depending on the outcome of the meeting tomorrow they could license or maybe sell.
Depending on the ProstaGene outcome (2) they will need to raise the remaining funding needed to get to the point with (1).
So I could see another Paulson raise in the short term, in fact I believe it is likely with selling on l2 being mostly retail, which showed up just recently.
From the 10k
All imo here.
1) The big partner with leronlimb is waiting for the BLA submission and the outcome of the mono pivotal meeting with the FDA. They need the cash to get past that point.
2) They have a potential partner in the ProstaGene test, we've seen the name, depending on the outcome of the meeting tomorrow they could license or maybe sell.
Depending on the ProstaGene outcome (2) they will need to raise the remaining funding needed to get to the point with (1).
So I could see another Paulson raise in the short term, in fact I believe it is likely with selling on l2 being mostly retail, which showed up just recently.
From the 10k
Quote:Our plan for the PCa Test is to successfully advance its development to obtain a Section 510(k) clearance from the FDA for commercial use or to out-license the proprietary technology to a third party.
Quote:We are currently evaluating strategic opportunities with respect to the assets acquired in our November 2018 acquisition of ProstaGene, including potential licensing or other opportunities to monetize intellectual property assets relating to prostate cancer diagnostics.
3
